Clinical Research Directory
Browse clinical research sites, groups, and studies.
L-arginine to Reduce Sympathetic Nerve Activity in CKD Patients
Sponsor: The University of Texas at Arlington
Summary
Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population. A potential signal driving sympathetic nerve activity (SNA) involves accumulation of the endogenous nitric oxide synthase (NOS) inhibitor asymmetric dimethylarginine (ADMA). ADMA is elevated in CKD and is a strong, independent predictor of future cardiovascular events in these patients. . The goal of this study is to determine whether overcoming the accumulation of endogenous ADMA with acute L-arginine infusion reduces SNA in CKD patients.
Official title: Role of Decreased Nitric Oxide in the Tonic Elevation of Resting Sympathetic Nerve Activity in Chronic Kidney Disease Patients
Key Details
Gender
All
Age Range
35 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2018-02-01
Completion Date
2026-12-31
Last Updated
2025-03-03
Healthy Volunteers
No
Conditions
Interventions
L-Arginine
Arginine Hydrochloride 60% concentration injection 15 g in 25 mL, contains arginine hydrochloride 600 mg/mL in water for injections to 25 mL.
Placebo
Saline
Locations (2)
University of Delaware
Newark, Delaware, United States
UT Southwestern
Dallas, Texas, United States